News
-
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Provides Update on Cladribine Program for Multiple Sclerosis, Sublingual Neurodegenerative Disease Patent, and Investor Relations Activities
BioNxt Solutions Inc. updates on sublingual Cladribine drug formulation program for Multiple Sclerosis, patent applications, and investor relations activities. Company aims to revolutionize drug delivery systems for CNS diseases -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
BioNxt Solutions Inc. receives positive international examination report from the European Patent Office for sublingual delivery patent application. Company to expand patent portfolio for neurodegenerative diseases and MS market -
-
-
COMMUNIQUÉ DE PRESSE
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
BioNxt Solutions Inc. signs non-binding LOI with Gen-Plus GmbH & Co KG, part of Conscio Group, for potential cooperation in pharmaceutical products and clinical trials. Details to follow -
